80 related articles for article (PubMed ID: 16986486)
1. [Prognostic value of the expression of thyreoglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies].
Kogan EA; Rozhkova EB; Seredin VP; Paltsev MA
Arkh Patol; 2006; 68(4):8-11. PubMed ID: 16986486
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis].
Zafón C; Castellví J; Obiols G
Endocrinol Nutr; 2010 Apr; 57(4):165-9. PubMed ID: 20403734
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma.
Zafon C; Obiols G; Castellví J; Tallada N; Baena JA; Simó R; Mesa J
Histopathology; 2007 Jan; 50(2):225-31. PubMed ID: 17222251
[TBL] [Abstract][Full Text] [Related]
5. [Biological investigation of thyroid cancer].
Douik H; Ghanem A; Jmal A; Harzallah L; Gara S; Abdennebi M; Boussen H; Guemira F
Tunis Med; 2006 Mar; 84(3):135-41. PubMed ID: 16755952
[TBL] [Abstract][Full Text] [Related]
6. RET oncogene expression of papillary thyroid carcinoma in Korea.
Chung KW; Chang MC; Noh DY; Oh SK; Choe KJ; Youn YK
Surg Today; 2004; 34(6):485-92. PubMed ID: 15170542
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of RET/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population.
Mishra A; Agrawal V; Krishnani N; Mishra SK
J Postgrad Med; 2009; 55(3):171-5. PubMed ID: 19884740
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
9. RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.
Nibu K; Otsuki N; Nakao K; Sugasawa M; Rothstein JL
Eur Arch Otorhinolaryngol; 2005 May; 262(5):368-73. PubMed ID: 15368067
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
12. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
13. Papillary carcinoma of the thyroid: a tumour still with no benign neoplastic counterpart.
Stephenson TJ
Histopathology; 2001 Nov; 39(5):536-8. PubMed ID: 11737313
[No Abstract] [Full Text] [Related]
14. RET proto-oncogene expression of papillary thyroid carcinomas in Thai patients.
Keelawat S; Shuangshoti S; Assanasen T; Thanakit V; Ruangvejvorachai P; Poumsuk U; Wannakrairot P
J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S5-12. PubMed ID: 17718263
[TBL] [Abstract][Full Text] [Related]
15. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease.
Khoo ML; Freeman JL; Witterick IJ; Irish JC; Rotstein LE; Gullane PJ; Asa SL
Arch Otolaryngol Head Neck Surg; 2002 Mar; 128(3):253-7. PubMed ID: 11886339
[TBL] [Abstract][Full Text] [Related]
16. [Expression of cytokeratins and ret in thyroid papillary carcinoma].
Zhou WX; Xiao Y; Liu TH; Luo YF; Cao JL
Zhonghua Bing Li Xue Za Zhi; 2003 Dec; 32(6):530-3. PubMed ID: 14761598
[TBL] [Abstract][Full Text] [Related]
17. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma.
Sethi K; Sarkar S; Das S; Rajput S; Mazumder A; Roy B; Patra S; Mohanty B; El-Naggar AK; Mandal M
J Exp Ther Oncol; 2011; 9(3):187-99. PubMed ID: 22070050
[TBL] [Abstract][Full Text] [Related]
18. [Thyroid papillary carcinoma].
Takano T
Nihon Rinsho; 2006 May; Suppl 1():469-72. PubMed ID: 16776192
[No Abstract] [Full Text] [Related]
19. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
20. [Thyroid carcinoma].
Tamaki H
Gan To Kagaku Ryoho; 2005 Apr; 32(4):561-5. PubMed ID: 15853229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
